The Simultaneous Onset of Pancreatitis and Colitis as Immune-related Adverse Events in a Patient Receiving Nivolumab Treatment for Renal Cell Carcinoma

Immune checkpoint inhibitors (ICIs), which have anti-tumor effects, are currently approved for treatment of several kinds of advanced malignancies. However, with their increasing use, a variety of immune-related adverse events (irAEs) in administered patients have been reported. We herein report a r...

Descripción completa

Detalles Bibliográficos
Autores principales: Yazaki, Tomotaka, Moriyama, Ichiro, Tobita, Hiroshi, Sonoyama, Hiroki, Okimoto, Eiko, Oka, Akihiko, Mishima, Yoshiyuki, Oshima, Naoki, Shibagaki, Kotaro, Kawashima, Kousaku, Ishimura, Norihisa, Nagami, Taichi, Maruyama, Riruke, Shiina, Hiroaki, Ishihara, Shunji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9177368/
https://www.ncbi.nlm.nih.gov/pubmed/34744104
http://dx.doi.org/10.2169/internalmedicine.7911-21
Descripción
Sumario:Immune checkpoint inhibitors (ICIs), which have anti-tumor effects, are currently approved for treatment of several kinds of advanced malignancies. However, with their increasing use, a variety of immune-related adverse events (irAEs) in administered patients have been reported. We herein report a rare case of the simultaneous onset of acute pancreatitis and colitis as irAEs during nivolumab treatment given to a patient with renal cell carcinoma, who then shown marked improvement with corticosteroid therapy.

Ejemplares similares